Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma

This study has been withdrawn prior to enrollment.
(Trial cancelled)
Sponsor:
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00415155
First received: December 20, 2006
Last updated: August 27, 2008
Last verified: August 2008

December 20, 2006
August 27, 2008
August 2008
January 2011   (final data collection date for primary outcome measure)
  • Phase 1: Determine recommended dose [ Time Frame: every cycle ] [ Designated as safety issue: Yes ]
  • Phase 2: Time to progression [ Time Frame: baseline to measured progressive disease ] [ Designated as safety issue: No ]
  • The recommended dose of LY2181308 in the advanced hepatocellular cancer (HCC) population
  • Time to progression for patients with advanced HCC who have received LY2181308
Complete list of historical versions of study NCT00415155 on ClinicalTrials.gov Archive Site
  • Phase 1: Safety [ Time Frame: every cycle ] [ Designated as safety issue: Yes ]
  • Phase 2: Overall Survival [ Time Frame: Baseline to date of death from any cause ] [ Designated as safety issue: Yes ]
  • Phase 2: Response rate [ Time Frame: Baseline to measured PD ] [ Designated as safety issue: No ]
  • Phase 2: Pharmacokinetics [ Time Frame: Cycle 1 and Cycle 2 ] [ Designated as safety issue: No ]
  • Phase 2: Safety [ Time Frame: every cycle ] [ Designated as safety issue: Yes ]
  • Overall survival time, progression-free survival, and time to progression of cancer symptoms
  • Safety
  • Response rate
  • Pharmacokinetics
  • Effect on circulating tumor cells and survivin expression
Not Provided
Not Provided
 
A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma
An Open Label, Single Arm, Phase 1b/2 Study With Pharmacokinetic Sampling to Evaluate LY2181308 in Patients With Advanced Hepatocellular Carcinoma

The primary objective of this study is to estimate the time to progressive disease for patients with advanced hepatocellular cancer who receive LY2181308.

Not Provided
Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Hepatocellular Carcinoma
Drug: LY2181308

Phase 1: 250mg, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle. (dose escalation)

Phase 2: phase 1 recommended dose, maximum 750mg dose, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle.

Experimental: A
Intervention: Drug: LY2181308
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
60
January 2011
January 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosed with hepatocellular cancer
  • Discontinued all previous therapies
  • At least 18 years of age

Exclusion Criteria:

  • Have other treatment options that are potentially curative or effective--such as surgical resection, liver transplant or percutaneous ablation, and/or transcatheter arterial embolization.
  • Transplanted liver
  • HIV positive
  • More than 2 previous systemic chemotherapy treatments
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   France,   Germany,   Spain
 
NCT00415155
10460, H8Z-MC-JACS
Not Provided
Chief Medical Officer, Eli Lilly
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
August 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP